CPT 80307: Presumptive Drug Test by Instrumented Analyzer
Commercial payers pay $137 on average nationally for this procedure.
CPT code 80307 describes a presumptive drug test performed by a laboratory analyst using instrumented chemistry analyzers to screen for one or more drug classes on a single date; service type: laboratory toxicology screening; typical site of service: clinical laboratory or hospital laboratory collection and testing setting.
Customize your policy alerts
Sign up for cpt 80307 policy alerts
Get alerted when payer policies referencing 80307 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial reimbursement for CPT 80307 clusters around BUCA’s average commercial rate of $136.60, with substantial differences among individual payers. Blue Cross Blue Shield displays the highest mean and a high median near $195.10, while Aetna and Cigna both show means near $61–$63 and medians in the low $50s. UnitedHealth Group’s mean is lower at $51.20 with a median of $37.30. These differences indicate a stratified market where BUCA sits between the higher Blue Cross Blue Shield levels and the lower Aetna/Cigna/UnitedHealth Group segment.
Dispersion measured by the interquartile range (P75–P25) highlights variation in contract pricing: Blue Cross Blue Shield’s IQR is $109.50 (P75 $242.80 minus P25 $141.30), the widest, while UnitedHealth Group is the tightest with an IQR of $33.20 (P75 $62.10 minus P25 $26.90). Cigna and BUCA show moderate dispersion at $50.70 and $76.30 respectively, and Aetna’s IQR is $24.00, indicating relatively concentrated pricing for Aetna and UnitedHealth Group compared with Blue Cross Blue Shield.